The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

Trial Profile

The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top